Although our results show that blocking of IL‐6R is a promising therapeutic opportunity in SLE especially with regard to skin symptoms, the association with increased autoantibody levels deserves further studies, as it might hamper the therapeutic usability of IL‐6R blockade in SLE. Here, IL6R is linked to systemic lupus erythematosus.